
Brian L. Pearlman, MD, FACP, reviews key considerations and supporting clinical data pertinent to the management of HCV nonresponders using currently available regimens.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Assess individual patient and disease factors when deciding between retreatment and watchful waiting strategies for patients who failed previous HCV treatment
- Formulate retreatment plans for relapsers and nonresponders to previous HCV therapy based on clinical data indicating optimal regimens, dosing, and duration
- Describe factors that influence response to retreatment for HCV infection